Can't Stop, Won't Stop the Search for Relief: Scratching the Surface of Itch and Inflammation in Moderate-to-Severe AD – Twitter Chat #1 Evaluation (ID: i769-13) Survey

Once you complete and submit the evaluation, please be sure to select your credit amount and click “Continue to Certificates” to claim credit.

2.Please select the option that best describes your practice setting:(Required.)

3.How many years have you been in practice?(Required.)

>21

11-20

1-10

<1

4.How many patients with AD do you manage each week?(Required.)

1 to 5

6 to 10

>11

I am not directly involved in patient care

5.After participating in this activity, how confident are you in the management of patients with AD in your practice?(Required.)

6.Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.(Required.)

Understand the rationale for use of targeted treatment for moderate-to-severe AD

Implementation of new treatment strategies to reduce disease activity and improve patient's QOL

Utilize JAKs based on their rapid antipruritic effects

Utilize JAKs based on the lack of immunogenicity concerns compared to mAbs

Utilize clinical trial findings for targeted therapies to identify patients who will potentially benefit from this treatment

Be aware of the status of emerging targeted therapies being studied in moderate-to-severe AD

Other (please explain)

7.How committed are you to making changes in your practice based on your participation in this activity?(Required.)

Very committed

Committed

Neutral

Not committed/do not plan to make changes (please explain)

8.What barriers do you see to making changes in your practice? Please select all that apply.(Required.)

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines and/or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

9.Which tools do you find most meaningful in measuring disease severity in patients with AD? Please select all that apply.(Required.)

Eczema Area and Severity Index (EASI)

Investigators Global Assessment Scale

Body surface area

Single item numeric 0-10 rating scale of itch

Peak Pruritis Numerical Rating Scale

Patient Global Assessment

12.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

13.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

14.If you indicated that you perceived commercial bias or influence, please describe: